(IN BRIEF) AstraZeneca and Daiichi Sankyo's Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated significant progress in treating HER2-low…
(IN BRIEF) AstraZeneca's Truqap, in combination with Faslodex, has received a positive recommendation from the European Medicines Agency (EMA) for…
(IN BRIEF) AstraZeneca announces positive outcomes from the ADRIATIC Phase III trial, revealing that its immunotherapy drug Imfinzi (durvalumab) demonstrated…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been acknowledged by the US…
(IN BRIEF) The European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for datopotamab deruxtecan (Dato-DXd), developed by…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted by the FDA…
(IN BRIEF) AstraZeneca's Tagrisso (osimertinib) demonstrates significant improvement in progression-free survival (PFS) for patients with unresectable, Stage III EGFR-mutated non-small…
(IN BRIEF) AstraZeneca has announced its definitive agreement to acquire Gracell Biotechnologies Inc. (NASDAQ: GRCL), a global biopharmaceutical company specializing…
(IN BRIEF) AstraZeneca has reported positive high-level results from the EMERALD-1 Phase III trial, demonstrating that its drug Imfinzi (durvalumab),…
(IN BRIEF) AstraZeneca's supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been granted Priority Review…
(IN BRIEF) AstraZeneca has unveiled data from four pivotal Phase III trials at the European Society for Medical Oncology (ESMO)…
(IN BRIEF) AstraZeneca is advancing its lung cancer portfolio at the International Association for the Study of Lung Cancer (IASLC)…
(IN BRIEF) AstraZeneca's new drug application (NDA) for capivasertib, in combination with Faslodex, has been accepted and granted Priority Review…
(IN BRIEF) AstraZeneca will showcase new data from its industry-leading Oncology pipeline and portfolio at the American Association for Cancer…
(PRESS RELEASE) CAMBRIDGE, 24-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced positive…
16-7-2013 — /europawire.eu/ — AstraZeneca today announced that it has entered into an agreement with the University of Cambridge and Cancer…